Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma

NACompletedINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Asthma
Interventions
GENETIC

Personalised medicine (Salmeterol)

If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.

GENETIC

Personalised medicine (Montelukast)

If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.

OTHER

Standard care

If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.

Trial Locations (5)

BN2 5BE

Brighton & Sussex University Hospitals NHS Trust, Brighton

ME8 0NZ

Kent, Surrey & Sussex CCGs, Gillingham

AB25 2ZG

NHS Grampian, Aberdeen

DD1 9SY

NHS Tayside, Dundee

NW1 0PE

Bart's Health NHS Trust, London

All Listed Sponsors
lead

University of Sussex

OTHER

NCT02758873 - Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma | Biotech Hunter | Biotech Hunter